Brief: Tenaya Therapeutics Says IND Applications For TN-201 And TN-301 Expected To Be Submitted In H2 Of 2022
10/01/2022 13:11
Jan 10 (Reuters) -
* TENAYA THERAPEUTICS INC - IND APPLICATIONS FOR TN-201 AND
TN-301
(PREVIOUSLY NAMED TYA-11631) EXPECTED TO BE SUBMITTED IN SECOND
HALF OF 2022
* TENAYA - SELECTION OF TN-401 AS DEVELOPMENT CANDIDATE FOR
TREATMENT OF GENETIC ARRHYTHMOGENIC RIGHT VENTRICULAR
CARDIOMYOPATHYDUE TO PKP2 GENE MUTATION
Source text for Eikon: ID:nBw8DJgzfa
Further company coverage: [ ]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027